{"id":26265,"date":"2021-04-13T07:24:00","date_gmt":"2021-04-13T00:24:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2021041307240026265"},"modified":"2021-04-13T21:39:15","modified_gmt":"2021-04-13T13:39:15","slug":"%e4%ba%9a%e7%9b%9b%e5%8c%bb%e8%8d%af%e5%a4%9a%e9%a1%b9%e6%9c%80%e6%96%b0%e4%b8%b4%e5%ba%8a%e5%89%8d%e8%bf%9b%e5%b1%95%e4%ba%ae%e7%9b%b82021aacr%e5%b9%b4%e4%bc%9a%ef%bc%8c%e5%91%88%e7%8e%b0%e5%a4%9a","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2021041307240026265","title":{"rendered":"\u4e9a\u76db\u533b\u836f\u591a\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55\u4eae\u76f82021AACR\u5e74\u4f1a\uff0c\u5448\u73b0\u591a\u79cd\u8054\u5408\u6cbb\u7597\u6f5c\u529b"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/1419966\/logo_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><p>\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022021\u5e744\u670813\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u5904\u4e8e\u4e34\u5e8a\u9636\u6bb5\u7684\u7814\u53d1\u4f01\u4e1a &#8212; \u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u57282021\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\u4e0a\u5c55\u793a\u4e86\u4e94\u4e2a\u5728\u7814\u539f\u521b\u65b0\u836f\u7684\u591a\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55\uff0c\u6d89\u53ca\u591a\u4e2a\u764c\u79cd\uff0c\u5e76\u5448\u73b0\u591a\u79cd\u8054\u5408\u7528\u836f\u7684\u6f5c\u529b\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>AACR\u5e74\u4f1a\u662f\u5168\u7403\u5386\u53f2\u6700\u60a0\u4e45\u3001\u89c4\u6a21\u6700\u5927\u7684\u80bf\u7624\u7814\u7a76\u5b66\u672f\u4f1a\u8bae\u4e4b\u4e00\u3002\u4f1a\u8bae\u5173\u6ce8\u9ad8\u8d28\u91cf\u80bf\u7624\u7814\u7a76\u53ca\u521b\u65b0\u7684\u5404\u4e2a\u65b9\u9762\uff0c\u662f\u5168\u7403\u80bf\u7624\u7814\u7a76\u7684\u7126\u70b9\uff0c\u5c06\u6c47\u96c6\u80bf\u7624\u9886\u57df\u7684\u6700\u524d\u6cbf\u7684\u7814\u7a76\u6210\u679c\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u5171\u6709\u4e03\u9879\u7814\u7a76\u6210\u679c\u5165\u9009\u672c\u6b21AACR\u5e74\u4f1a\u58c1\u62a5\u5c55\u793a\uff1a<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"1\" class=\"prntblns\">\n<tbody>\n<tr>\n<td nowrap class=\"prnsbts prnrbrs prnvab prnsbbs prnpl6 prnsbls prnpr6\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u4ea7\u54c1<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u6807\u9898<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen3\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u6458\u8981\u7f16\u53f7<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\" nowrap class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">HQP1351<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">FMS-like tyrosine kinase 3 (FLT3) inhibition by <br \/>olverembatinib (HQP1351) downregulates MCL-1 and <br \/>synergizes with BCL-2 inhibitor APG-2575 in preclinical <br \/>models of FLT3-mutant acute myeloid leukemia (AML)<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">FMS\u6837\u916a\u6c28\u9178\u6fc0\u91763 (FLT3) \u6291\u5236\u5242\u5965\u745e\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u901a<br \/>\u8fc7\u4e0b\u8c03MCL-1\u4e0eBCL-2\u6291\u5236\u5242APG-2575\u5728FLT3\u7a81\u53d8\u578b\u6025\u6027<br \/>\u9ad3\u7cfb\u767d\u8840\u75c5(AML)\u7684\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u7684\u534f\u540c\u4f5c\u7528<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">1096<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">ATP-site inhibitor olverembatinib, HQP1351, enhanced the <br \/>effect of allosteric inhibitor on the resistance conferred by <br \/>the compound mutations of BCR-ABL<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">ATP\u7ed3\u5408\u4f4d\u70b9\u6291\u5236\u5242olverembatinib\uff08HQP1351\uff09\u589e\u5f3a\u53d8\u6784\u6291\u5236<br \/>\u5242\u5bf9BCR-ABL\u590d\u5408\u7a81\u53d8\u5f15\u8d77\u7684\u8010\u836f\u7684\u4f5c\u7528<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">1463<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\" nowrap class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">APG-2575<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">BCL-2 inhibitor APG-2575 and homoharringtonine (HHT) <br \/>synergistically induces apoptosis and inhibits tumor growth <br \/>in preclinical models of acute myeloid leukemia and <br \/>myelodysplastic syndromes (AML\/MDS)<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">BCL-2\u6291\u5236\u5242APG-2575\u548c\u9ad8\u4e09\u5c16\u6749\u916f\u78b1(HHT)\u5728\u6025\u6027\u9ad3\u7cfb\u767d<br \/>\u8840\u75c5\uff08AML\uff09\u548c\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81(MDS)\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u8bf1\u5bfc<br \/>\u7ec6\u80de\u51cb\u4ea1\u548c\u6291\u5236\u80bf\u7624\u751f\u957f\u7684\u534f\u540c\u4f5c\u7528<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">981<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Inhibition of BCL-2 (by APG-2575) and CDK4\/6 <br \/>synergistically induces cell cycle arrest and apoptosis in ER\u207a&nbsp;<br \/>breast cancer<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">BCL-2\u6291\u5236\uff08APG-2575\uff09\u4e0eCDK4\/6\u6291\u5236\u534f\u540c\u8bf1\u5bfcER\u207a\u4e73\u817a\u764c\u7ec6<br \/>\u80de\u7684\u5468\u671f\u963b\u6ede\u548c\u7ec6\u80de\u51cb\u4ea1<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">976<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">APG-1387<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Therapeutic potential of inhibitor of apoptosis protein (IAP) <br \/>inhibitor APG-1387 combined with DR5 agonist monoclonal <br \/>antibody (mAb) CTB-006 in preclinical models of solid <br \/>tumors<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u51cb\u4ea1\u6291\u5236\u86cb\u767d(IAP)\u6291\u5236\u5242APG-1387\u8054\u5408DR5\u6fc0\u52a8\u5242CTB-006<br \/>\u5355\u514b\u9686\u6297\u4f53(mAb)\u5728\u5b9e\u4f53\u7624\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u7684\u6cbb\u7597\u6f5c\u529b\u7814\u7a76<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">1924<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">APG-1252<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to <br \/>overcome apoptotic blockade in neuroendocrine neoplasm <br \/>(NEN) <\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">APG-1252 (pelcitoclax)\u6291\u5236 BCL-xL\u514b\u670d\u795e\u7ecf\u5185\u5206\u6ccc\u80bf\u7624(NEN<br \/>)\u7ec6\u80de\u7684\u51cb\u4ea1\u963b\u65ad\u7814\u7a76<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">984<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td nowrap class=\"prngen4\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">APG-2449<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">Focal adhesion kinase (FAK) inhibitor APG-2449 sensitizes <br \/>ovarian tumors to chemotherapy via CD44 downregulation<\/span><\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\">\u5c40\u7076\u7c98\u9644\u6fc0\u9176(FAK)\u6291\u5236\u5242APG-2449\u901a\u8fc7\u4e0b\u8c03CD44\u589e\u5f3a\u5375\u5de2<br \/>\u764c\u5bf9\u5316\u7597\u7684\u654f\u611f\u6027<\/span><\/p>\n<\/td>\n<td nowrap class=\"prngen5\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">968<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>\u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u8868\u793a\uff1a\u201c\u4eca\u5e74AACR\u5c55\u793a\u7684\u6210\u679c\u662f\u6211\u4eec\u5728\u4ee5\u89e3\u51b3\u60a3\u8005\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u5bfc\u5411\u4e0b\u7684\u8fdb\u4e00\u6b65\u63a2\u7d22\uff0c\u4e3a\u516c\u53f8\u591a\u4e2a\u91cd\u8981\u54c1\u79cd\u4e0e\u5176\u4ed6\u9776\u70b9\u3001\u5176\u4ed6\u673a\u7406\u836f\u7269\u7684\u8054\u5408\u6cbb\u7597\u63d0\u4f9b\u4e86\u5145\u5206\u7684\u79d1\u5b66\u652f\u6301\u3002\u80bf\u7624\u7684\u8054\u5408\u6cbb\u7597\u662f\u672a\u6765\u53d1\u5c55\u7684\u8d8b\u52bf\uff0c\u6211\u4eec\u5e0c\u671b\u80fd\u83b7\u5f97\u66f4\u79ef\u6781\u7684\u8fdb\u5c55\uff0c\u65e9\u65e5\u9020\u798f\u60a3\u8005\u3002\u201d<\/p>\n<p><b>FMS-like tyrosine kinase 3 (FLT3) inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 in preclinical models of FLT3-mutant acute myeloid leukemia (AML)<\/b><\/p>\n<p><b>FMS\u6837\u916a\u6c28\u9178\u6fc0\u91763 (FLT3) \u6291\u5236\u5242\u5965\u745e\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u901a\u8fc7\u4e0b\u8c03MCL-1\u4e0eBCL-2\u6291\u5236\u5242APG-2575\u5728FLT3\u7a81\u53d8\u578b\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5(AML)\u7684\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u7684\u534f\u540c\u4f5c\u7528<\/b><\/p>\n<ul type=\"disc\">\n<li><b>\u6458\u8981\u7f16\u53f7\uff1a<\/b><b>1096<\/b> <\/li>\n<li><b>\u80cc\u666f\uff1a<\/b><\/li>\n<\/ul>\n<p>AML\u5360\u6210\u5e74\u4eba\u6025\u6027\u767d\u8840\u75c5\u768480\uff05\uff0c\u5176\u4e2d\u5927\u7ea630\uff05\u7684AML\u60a3\u8005\u643a\u5e26FLT3\u57fa\u56e0\u7a81\u53d8\uff0c\u4e14\u9884\u540e\u4e0d\u826f\u3002\u5c3d\u7ba1\u9009\u62e9\u6027FLT3\u6291\u5236\u5242\u5177\u6709\u6297\u80bf\u7624\u4f5c\u7528\uff0c\u4f46\u5bf9\u8fd9\u4e9b\u836f\u7269\u7684\u8010\u836f\u6027\u662f\u4e34\u5e8a\u4e0aAML\u6cbb\u7597\u7684\u5de8\u5927\u6311\u6218\u3002\u6297\u51cb\u4ea1\u86cb\u767dBCL-2\u5728AML\u4e2d\u7684\u8868\u8fbe\u7ecf\u5e38\u5931\u8c03\uff0c\u662f\u5bf9FLT3\u6291\u5236\u5242\u7684\u8010\u53d7\u7684\u4e3b\u8981\u539f\u56e0\u4e4b\u4e00\u3002\u5728\u8fd9\u9879\u7814\u7a76\u4e2d\uff0c\u6211\u4eec\u5728\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\uff0c\u63a2\u7d22\u4e86\u591a\u6fc0\u9176\u6291\u5236\u5242HQP1351\u901a\u8fc7\u6291\u5236FLT3\u4e0eBCL-2\u9009\u62e9\u6027\u6291\u5236\u5242APG-2575\u8054\u5408\u7528\u836f\u5728FLT3\u7a81\u53d8\u7684AML\u7684\u7597\u6548\u548c\u4f5c\u7528\u673a\u5236\u3002<\/p>\n<ul type=\"disc\">\n<li><b>\u7ed3\u8bba\uff1a<\/b><\/li>\n<\/ul>\n<p>\u4e34\u5e8a\u524d\u7814\u7a76\u6570\u636e\u8868\u660e\uff0cHQP1351\u901a\u8fc7\u6291\u5236FLT3\u86cb\u767d\u53ca\u5176\u4e0b\u6e38\u4fe1\u53f7\u901a\u8def\uff0c\u4e0b\u8c03MCL-1\u86cb\u767d\u7684\u8868\u8fbe\uff0c\u4ece\u800c\u4e0eBCL-2\u6291\u5236\u5242APG-2575\u534f\u540c\u589e\u5f3aFLT3-ITD\u7a81\u53d8\u7684AML\u7ec6\u80de\u7684\u51cb\u4ea1\u3002\u8be5\u7ed3\u679c\u4e3aHQP1351\u548cAPG-2575\u8054\u5408\u7528\u836f\u5728FLT3-ITD\u7a81\u53d8AML\u60a3\u8005\u4e2d\u7684\u4e34\u5e8a\u5f00\u53d1\u63d0\u4f9b\u4e86\u79d1\u5b66\u4f9d\u636e\u3002<\/p>\n<p><b>ATP-site inhibitor olverembatinib, HQP1351, enhanced the effect of allosteric inhibitor on the resistance conferred by the compound mutations of BCR-ABL<\/b><\/p>\n<p><b>ATP\u7ed3\u5408\u4f4d\u70b9\u6291\u5236\u5242olverembatinib\uff08HQP1351\uff09\u589e\u5f3a\u53d8\u6784\u6291\u5236\u5242\u5bf9BCR-ABL\u590d\u5408\u7a81\u53d8\u5f15\u8d77\u7684\u8010\u836f\u7684\u4f5c\u7528<\/b><\/p>\n<ul type=\"disc\">\n<li><b>\u6458\u8981\u7f16\u53f7\uff1a<\/b><b>1463<\/b> <\/li>\n<li><b>\u80cc\u666f\uff1a<\/b><\/li>\n<\/ul>\n<p>\u5229\u7528\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\u9776\u5411BCR-ABL\u7684ATP\u7ed3\u5408\u4f4d\u70b9\u662f\u6cbb\u7597Ph+\u767d\u8840\u75c5\u7684\u6709\u6548\u624b\u6bb5\u3002\u7136\u800c\uff0c\u770b\u95e8\u4f4d\u70b9\u7684T315I\u7a81\u53d8\u4ee5\u53ca\u590d\u5408\u7a81\u53d8\u4f1a\u5bfc\u81f4\u5bf9\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\u7684\u8010\u836f\u3002\u53d8\u6784\u6291\u5236\u5242asciminib (ABL001)\u53ef\u4ee5\u901a\u8fc7\u7ed3\u5408\u5230BCR-ABL\u7684\u8089\u8c46\u853b\u9170\u57fa\u7ed3\u5408\u4f4d\u70b9\uff0c\u6709\u6548\u5730\u6291\u5236\u5176\u6fc0\u9176\u6d3b\u6027\u3002Asciminib\u548cponatinib\u8054\u5408\u4f7f\u7528\u4ec5\u53ef\u4ee5\u514b\u670d\u90e8\u5206\u7531\u590d\u5408\u7a81\u53d8\u5bfc\u81f4\u7684\u8010\u836f\u3002Olverembatinib (HQP1351)\u662f\u65b0\u4e00\u4ee3\u7684\u9776\u5411BCR-ABL\u7684\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff0c\u76ee\u524d\u8fd9\u6b63\u5f00\u53d1\u7528\u4e8e\u6cbb\u7597\u96be\u6cbb\u548c\u590d\u53d1\u7684\u6162\u6027\u9ad3\u6027\u767d\u8840\u75c5\u3002\u672c\u7814\u7a76\u7684\u76ee\u7684\u662f\u8bc4\u4f30\u901a\u8fc7\u8054\u5408\u4f7f\u7528olverembatinib\u548casciminib\uff0c\u540c\u65f6\u9776\u5411BCR-ABL\u7684ATP\u7ed3\u5408\u53e3\u888b\u548c\u53d8\u6784\u4f4d\u70b9\uff0c\u662f\u5426\u53ef\u4ee5\u6291\u5236\u643a\u5e26\u590d\u5408\u7a81\u53d8\u7684\u6fc0\u9176\u6d3b\u6027\u3002<\/p>\n<ul type=\"disc\">\n<li><b>\u7ed3\u8bba\uff1a<\/b><\/li>\n<\/ul>\n<p>\u4e34\u5e8a\u524d\u7814\u7a76\u6570\u636e\u8868\u660e\uff0cATP\u7ed3\u5408\u4f4d\u70b9\u6291\u5236\u5242olverembatinib\u4e0e\u53d8\u6784\u6291\u5236\u5242\u8054\u5408\u4f7f\u7528\u5bf9\u643a\u5e26BCR-ABL\u5355\u7a81\u53d8\u6216\u590d\u5408\u7a81\u53d8\u7684\u80bf\u7624\u7ec6\u80de\u5177\u6709\u534f\u540c\u6297\u80bf\u7624\u4f5c\u7528\u3002\u8be5\u65b0\u7b56\u7565\u6709\u52a9\u4e8e\u514b\u670d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\u6cbb\u7597\u540e\u7684\u7ee7\u53d1\u6027\u590d\u5408\u7a81\u53d8\u3002<\/p>\n<p><b>BCL-2 inhibitor APG-2575 and homoharringtonine (HHT) synergistically induces apoptosis and inhibits tumor growth in preclinical models of acute myeloid leukemia and myelodysplastic syndromes (AML\/MDS)<\/b><\/p>\n<p><b>BCL-2\u6291\u5236\u5242APG-2575\u548c\u9ad8\u4e09\u5c16\u6749\u916f\u78b1(HHT)\u5728\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u548c\u9aa8\u9ad3\u589e\u751f\u5f02\u5e38\u7efc\u5408\u5f81(MDS)\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u8bf1\u5bfc\u7ec6\u80de\u51cb\u4ea1\u548c\u6291\u5236\u80bf\u7624\u751f\u957f\u7684\u534f\u540c\u4f5c\u7528<\/b><\/p>\n<ul type=\"disc\">\n<li><b>\u6458\u8981\u7f16\u53f7\uff1a<\/b><b>981<\/b> <\/li>\n<li><b>\u80cc\u666f\uff1a<\/b><\/li>\n<\/ul>\n<p>\u5728\u8fc7\u53bb\u7684\u5341\u5e74\u4e2d\uff0c\u968f\u7740\u591a\u6b3e\u9776\u5411\u6cbb\u7597\u836f\u7269\u7684\u6279\u51c6,AML\u7684\u6cbb\u7597\u72b6\u51b5\u5f97\u5230\u4e86\u663e\u8457\u6539\u5584\uff0c\u5ba2\u89c2\u7f13\u89e3\u7387\u548c\u603b\u4f53\u751f\u5b58\u7387\u5747\u6709\u6240\u63d0\u9ad8\u3002BCL-2\u6291\u5236\u5242\u4e0e\u53bb\u7532\u57fa\u5316\u836f\u7269\u6216\u4f4e\u5242\u91cf\u963f\u7cd6\u80de\u82f7\uff08Ara-C\uff09\u8054\u5408\u7528\u836f\u4e5f\u53ef\u6709\u6548\u7528\u4e8e\u6cbb\u7597\u5148\u524d\u672a\u63a5\u53d7\u8fc7\u6cbb\u7597\uff0c\u4e0d\u9002\u5408\u63a5\u53d7\u6807\u51c6\u5148\u5bfc\u6cbb\u7597\u7684\u8001\u5e74AML\u60a3\u8005\u3002\u4f46\u662f\uff0c\u5982\u679c\u80bf\u7624\u7ec6\u80de\u8868\u8fbe\u4e86\u8f83\u9ad8\u6c34\u5e73\u7684\u6297\u51cb\u4ea1\u86cb\u767dMCL-1\uff0cBCL-2\u6291\u5236\u5242\u7684\u4f5c\u7528\u901a\u5e38\u4f1a\u51cf\u5f31\u3002\u56e0\u6b64\uff0c\u5f15\u5165\u8054\u5408\u7597\u6cd5\u4ee5\u6291\u5236MCL-1\u6c34\u5e73\u662f\u4e00\u79cd\u65b0\u7684\u6cbb\u7597\u7b56\u7565\u3002HHT \u662f\u4e00\u79cd\u86cb\u767d\u5408\u6210\u6291\u5236\u5242\uff0c\u53ef\u6291\u5236MCL-1\u7684\u5408\u6210\u3002\u9ad8\u4e09\u5c16\u6749\u916f\u78b1\uff08HHT\uff09\u5df2\u7ecf\u5728\u4e2d\u56fdAML\u60a3\u8005\u4e2d\u5e7f\u6cdb\u4f7f\u7528\u4e8630\u5e74\u3002\u672c\u7814\u7a76\u63a2\u7d22\u4e86\u5904\u4e8e\u4e34\u5e8a\u9636\u6bb5\u7684\u9009\u62e9\u6027BCL-2\u6291\u5236\u5242APG-2575\u4e0eHHT\u8054\u5408\u7528\u836f\u5728AML\u548cMDS\u7ec6\u80de\u4ee5\u53ca\u5c0f\u9f20\u5f02\u79cd\u79fb\u690d\u80bf\u7624\u6a21\u578b\u4e2d\u7684\u534f\u540c\u6297\u80bf\u7624\u4f5c\u7528\u3002<\/p>\n<ul type=\"disc\">\n<li><b>\u7ed3\u8bba\uff1a<\/b><\/li>\n<\/ul>\n<p>\u4e34\u5e8a\u524d\u7814\u7a76\u6570\u636e\u8868\u660e\uff0c\u5728\u4e34\u5e8a\u524dAML\/MDS\u6a21\u578b\u4e2d\uff0cAPG-2575\u4e0eHHT\u8054\u5408\u7528\u836f\u5177\u6709\u534f\u540c\u6297\u80bf\u7624\u4f5c\u7528\u3002 HHT\u6291\u5236MCL-1\u86cb\u767d\uff0c\u963b\u6b62\u6216\u6d88\u9664MCL-1\uff1aBIM\uff0cMCL-1\uff1aPUMA\u548cMCL-1\uff1aBAK\u590d\u5408\u7269\u7684\u5f62\u6210\uff0c\u4ece\u800c\u4fc3\u4f7f\u51cb\u4ea1\u86cb\u767d\u5145\u5206\u53c2\u4e0e\u80bf\u7624\u7ec6\u80de\u51cb\u4ea1\u7684\u8bf1\u5bfc\u3002\u8fd9\u4e9b\u7ed3\u679c\u4e3aAPG-2575\u4e0eHHT\u8054\u5408\u7528\u836f\u7684\u4e34\u5e8a\u5f00\u53d1\u63d0\u4f9b\u4e86\u79d1\u5b66\u4f9d\u636e\u3002<\/p>\n<p><b>Inhibition of BCL-2 (by APG-2575) and CDK4\/6 synergistically induces cell cycle arrest and apoptosis in ER<\/b><b>\u207a<\/b><b>&nbsp;breast cancer<\/b><\/p>\n<p><b>BCL-2\u6291\u5236\uff08APG-2575\uff09\u4e0eCDK4\/6\u6291\u5236\u534f\u540c\u8bf1\u5bfcER<\/b><b>\u207a<\/b><b>\u4e73\u817a\u764c\u7ec6\u80de\u7684\u5468\u671f\u963b\u6ede\u548c\u7ec6\u80de\u51cb\u4ea1<\/b><\/p>\n<ul type=\"disc\">\n<li><b>\u6458\u8981\u7f16\u53f7\uff1a<\/b><b>976<\/b> <\/li>\n<li><b>\u80cc\u666f\uff1a<\/b><\/li>\n<\/ul>\n<p>\u96cc\u6fc0\u7d20\u53d7\u4f53\u8868\u8fbe\u9633\u6027(ER+) \/\u4eba\u7c7b\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f532\u8868\u8fbe\u9634\u6027(HER2-)\u7684\u4e73\u817a\u764c\u7ea6\u5360\u6240\u6709\u4e73\u817a\u764c\u75c5\u4f8b\u768475\uff05\uff0c\u662f\u6700\u5e38\u89c1\u7684\u4e73\u817a\u764c\u4e9a\u578b\u3002\u5185\u5206\u6ccc\u6cbb\u7597\u548c\u7ec6\u80de\u5468\u671f\u86cb\u767d\u4f9d\u8d56\u6027\u6fc0\u91764\/6\u6291\u5236\u5242\uff08CDK4\/6i\uff09\u8054\u5408\u6cbb\u7597\u662f\u65e9\u671f\u8f6c\u79fb\u6027ER+\u4e73\u817a\u764c\u6807\u51c6\u6cbb\u7597\u65b9\u6848\u3002\u7136\u800c\u8054\u5408\u6cbb\u7597\u540e\u60a3\u8005\u4ecd\u4e0d\u53ef\u907f\u514d\u8010\u836f\u590d\u53d1\u3002\u590d\u53d1\u96be\u6cbb\u6027\u4e73\u817a\u764c\u60a3\u8005\u751f\u5b58\u7387\u8f83\u4f4e\uff0c\u4e9f\u9700\u65b0\u7684\u6cbb\u7597\u65b9\u6cd5\u548c\u8054\u5408\u6cbb\u7597\u65b9\u6848\u3002\u7814\u7a76\u53d1\u73b0\uff0c80\uff05\u539f\u53d1\u6027\u548c\u8f6c\u79fb\u6027ER+ \u4e73\u817a\u764c\u4e2d\u5b58\u5728\u6297\u51cb\u4ea1\u86cb\u767dBCL-2\u8fc7\u8868\u8fbe\u3002\u65e2\u5f80\u7814\u7a76\u663e\u793a\uff0c\u6b63\u5728\u6076\u6027\u8840\u6db2\u80bf\u7624\u4e2d\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c\u7684BCL-2\u9009\u62e9\u6027\u6291\u5236\u5242APG-2575\u8054\u5408FDA\u6279\u51c6\u7528\u4e8eER+\u4e73\u817a\u764c\u6cbb\u7597\u7684CDK4\/6\u6291\u5236\u5242\u5e15\u535a\u897f\u5c3c\uff08Palbociclib\uff09\u5728ER+\u4e73\u817a\u764c\u5f02\u79cd\u79fb\u690d\u6a21\u578b\u4e2d\u534f\u540c\u589e\u5f3a\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u5176\u4e2d\u5305\u62ec\u5bf9\u4ed6\u83ab\u897f\u82ac\uff08Tamoxifen\uff09\u8010\u836f\u6216CDK4\/6i\u6cbb\u7597\u540e\u590d\u53d1\u8fdb\u5c55\u7684\u6076\u6027\u80bf\u7624\u6a21\u578b\u3002\u672c\u7814\u7a76\u4f53\u5916\u63a2\u7d22APG-2575\u5355\u836f\u53ca\u8054\u5408CDK4\/6\u6291\u5236\u5242\u5728ER+\/HER2-\u4e73\u817a\u764c\u7ec6\u80deMCF-7\u4e2d\u8bf1\u5bfc\u51cb\u4ea1\u4f5c\u7528\u53ca\u5176\u4f5c\u7528\u673a\u5236\u3002<\/p>\n<ul type=\"disc\">\n<li><b>\u7ed3\u8bba\uff1a<\/b><\/li>\n<\/ul>\n<p>\u4e34\u5e8a\u524d\u7814\u7a76\u6570\u636e\u8868\u660e\uff0c\u5e15\u535a\u897f\u5c3c\u901a\u8fc7\u8bf1\u5bfc\u7ec6\u80de\u5468\u671f\u963b\u6ede\u4ece\u800c\u5bfc\u81f4\u7ec6\u80de\u8870\u8001\uff0c\u800cAPG-2575\u4e0d\u4ec5\u8bf1\u5bfc\u7ec6\u80de\u5468\u671f\u963b\u6ede\uff0c\u800c\u4e14\u8fd8\u53ef\u4ee5\u89e6\u53d1\u7ec6\u80de\u51cb\u4ea1\u3002BCL-2\u548cCDK4\/6\u6291\u5236\u5242\u8054\u5408\u7528\u836f\u80fd\u8fdb\u4e00\u6b65\u534f\u540c\u8bf1\u5bfc\u7ec6\u80de\u5468\u671f\u963b\u6ede\uff0c\u6700\u91cd\u8981\u7684\u662f\u6709\u6548\u5730\u6e05\u9664\u4e86\u7531\u5e15\u535a\u897f\u5c3c\u8bf1\u5bfc\u4ea7\u751f\u7684\u8870\u8001\u7ec6\u80de\uff0c\u8bf1\u5bfc\u764c\u7ec6\u80de\u51cb\u4ea1\u3002\u6211\u4eec\u7684\u7814\u7a76\u7ed3\u679c\u4e3a\u8fdb\u4e00\u6b65\u7814\u7a76APG-2575\u5355\u836f\u53ca\u4e0e\u5e15\u535a\u897f\u5c3c\u8054\u5408\u7528\u836f\u4ee5\u6539\u5584ER+\u4e73\u817a\u764c\u60a3\u8005\u6cbb\u7597\u6548\u679c\u63d0\u4f9b\u4e86\u5f3a\u6709\u529b\u7406\u8bba\u4f9d\u636e\u3002<\/p>\n<p><b>Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors<\/b><\/p>\n<p><b>\u51cb\u4ea1\u6291\u5236\u86cb\u767d<\/b><b>(IAP)\u6291\u5236\u5242APG-1387\u8054\u5408DR5\u6fc0\u52a8\u5242CTB-006\u5355\u514b\u9686\u6297\u4f53(mAb)\u5728\u5b9e\u4f53\u7624\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u7684\u6cbb\u7597\u6f5c\u529b\u7814\u7a76<\/b><\/p>\n<ul type=\"disc\">\n<li><b>\u6458\u8981\u7f16\u53f7\uff1a<\/b><b>1924<\/b> <\/li>\n<li><b>\u80cc\u666f\uff1a<\/b><\/li>\n<\/ul>\n<p>TNF\u76f8\u5173\u51cb\u4ea1\u8bf1\u5bfc\u914d\u4f53\uff08TRAIL\uff09\u53d7\u4f53\uff08DR4\u6216DR5\uff09\u6fc0\u52a8\u5242\u53ef\u4ee5\u9009\u62e9\u6027\u7684\u8bf1\u5bfc\u764c\u7ec6\u80de\u51cb\u4ea1\uff0c\u662f\u6f5c\u5728\u7684\u764c\u75c7\u6cbb\u7597\u836f\u7269\u3002\u7136\u800c\uff0c\u5176\u5728\u4e34\u5e8a\u7814\u7a76\u4e2d\uff0c\u5176\u6548\u679c\u53d7\u5230\u539f\u53d1\u6027\u6216\u83b7\u5f97\u6027\u8010\u836f\u7684\u9650\u5236\u3002\u7b2c\u4e8c\u79cd\u7ebf\u7c92\u4f53\u884d\u751fcaspase\u6fc0\u6d3b\u7269\uff08SMAC\uff09\u6a21\u62df\u7269\uff0c\u53ef\u4ee5\u62ee\u6297IAP\uff0c\u901a\u8fc7caspase-8\u901a\u8def\u589e\u5f3aTRAIL\u8bf1\u5bfc\u764c\u7ec6\u80de\u51cb\u4ea1\u7684\u654f\u611f\u6027\u3002\u5728\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u6211\u4eec\u8bc4\u4f30IAP\u5c0f\u5206\u5b50\u62ee\u6297\u5242APG-1387\u8054\u5408DR-5\u6297\u4f53\u6fc0\u52a8\u5242CTB-006\u836f\u6548\u3002\u5176\u4e2dAPG-1387\u548cCTB-006\u4e24\u79cd\u836f\u7269\u5747\u5904\u4e8e\u5b9e\u4f53\u7624\u4e34\u5e8aI\/II\u671f\u5f00\u53d1\u9636\u6bb5\u3002<\/p>\n<ul type=\"disc\">\n<li><b>\u7ed3\u8bba\uff1a<\/b><\/li>\n<\/ul>\n<p>\u4e34\u5e8a\u524d\u7814\u7a76\u6570\u636e\u8868\u660e\uff0cAPG-1387\u8054\u5408CTB-006\u5177\u6709\u534f\u540c\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u8054\u5408\u7ec4\u7684\u6240\u6709\u5c0f\u9f20\u80bf\u7624\u5747\u51fa\u73b0\u5b8c\u5168\u7f13\u89e3\uff08CR\uff09\u3001\u90e8\u5206\u7f13\u89e3\uff08PR\uff09\u548c\u75be\u75c5\u7a33\u5b9a\uff08SD\uff09\u3002\u8be5\u7ed3\u679c\u4e3aAPG-1387\u8054\u5408CTB-006\u5728\u5b9e\u4f53\u7624\u6cbb\u7597\u7684\u4e34\u5e8a\u5f00\u53d1\u4e0a\u63d0\u4f9b\u4e86\u79d1\u5b66\u4f9d\u636e\u3002<\/p>\n<p><b>Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN)<\/b><\/p>\n<p><b>APG-1252 (pelcitoclax)\u6291\u5236 BCL-xL\u514b\u670d\u795e\u7ecf\u5185\u5206\u6ccc\u80bf\u7624(NEN)\u7ec6\u80de\u7684\u51cb\u4ea1\u963b\u65ad\u7814\u7a76<\/b><\/p>\n<ul type=\"disc\">\n<li><b>\u6458\u8981\u7f16\u53f7\uff1a<\/b><b>984<\/b> <\/li>\n<li><b>\u80cc\u666f\uff1a<\/b><\/li>\n<\/ul>\n<p>\u5728\u795e\u7ecf\u5185\u5206\u6ccc\u80bf\u7624\u7684\u6cbb\u7597\u65b9\u9762\uff0c\u76ee\u524d\u7684\u9776\u5411\u7597\u6cd5\u5982VEGFR\u6291\u5236\u5242\u8212\u5c3c\u66ff\u5c3c\u548cmTOR\u6291\u5236\u5242\u4f9d\u7ef4\u83ab\u53f8\u867d\u7136\u53ef\u4ee5\u5ef6\u957fG1\u548cG2\u7ea7\u795e\u7ecf\u5185\u5206\u6ccc\u80bf\u7624(NET) \u60a3\u8005\u7684\u65e0\u8fdb\u5c55\u751f\u5b58(PFS)\uff0c\u4f46\u5ba2\u89c2\u5e94\u7b54\u7387\u4ecd\u8f83\u4f4e\u3002\u53e6\u5916\uff0c\u4ee5\u94c2\u7c7b\u4e3a\u57fa\u7840\u6cbb\u7597\u7684\u665a\u671f\u795e\u7ecf\u5185\u5206\u6ccc\u764c(NEC)\u60a3\u8005\u7684\u4e2d\u4f4dPFS\u4e5f\u53ea\u67093 &#8211; 4\u4e2a\u6708\u3002\u56e0\u6b64\uff0c\u9700\u8981\u66f4\u52a0\u6709\u6548\u7684\u6cbb\u7597\u65b9\u6848\u6765\u6539\u5584\u4e34\u5e8a\u7ed3\u679c\u3002\u672c\u7814\u7a76\u63a2\u8ba8\u4e86BCL-2\u5bb6\u65cf\u6297\u51cb\u4ea1\u86cb\u767d\u662f\u5426\u5728NEN\u80bf\u7624\u7684\u53d1\u751f\u4e2d\u53d1\u6325\u4f5c\u7528\uff0c\u4ee5\u53ca\u76ee\u524d\u5904\u4e8e\u4e34\u5e8a\u9636\u6bb5\u7684BCL-2\/BCL-xL\u53cc\u9776\u70b9\u6291\u5236\u5242APG-1252\u662f\u5426\u53ef\u80fd\u514b\u670dNEN\u7684\u5185\u5728\u51cb\u4ea1\u963b\u6ede\u3002<\/p>\n<ul type=\"disc\">\n<li><b>\u7ed3\u8bba\uff1a<\/b><\/li>\n<\/ul>\n<p>\u4e34\u5e8a\u524d\u7814\u7a76\u6570\u636e\u8868\u660e\uff0cBCL-xL\u5728NEN\u4e2d\u8d77\u7740\u91cd\u8981\u4f5c\u7528\u3002\u7ec6\u80de\u5bf9BCL-2\/BCL-xL\u6291\u5236\u5242APG-1252-M1\u7684\u654f\u611f\u6027\u4e0eBCL-xL\u590d\u5408\u7269\u7684\u672c\u5e95\u6c34\u5e73\u76f8\u5173\u3002\u5728NEN\u60a3\u8005\u6837\u672c\u4e2d\uff0cMCL-1\u4e5f\u51fa\u73b0\u9ad8\u8868\u8fbe\uff0c\u8fd9\u610f\u5473\u7740\u5b83\u53ef\u80fd\u5bf9APG-1252\u7684\u654f\u611f\u6027\u4ea7\u751f\u8d1f\u8c03\u63a7\u4f5c\u7528\u3002BCL-xL\u548cMCL-1\u86cb\u767d\u7684\u540c\u65f6\u9ad8\u8868\u8fbe\u63d0\u793a\u9488\u5bf9\u8fd9\u4e24\u79cd\u86cb\u767d\u7684\u8054\u5408\u6cbb\u7597\u53ef\u80fd\u5bf9NEN\u66f4\u6709\u6548\u3002\u6211\u4eec\u7684\u7814\u7a76\u7ed3\u679c\u4e3a\u5f00\u53d1\u7528\u4e8eNEN\u6cbb\u7597\u7684BCL-2\/BCL-xL\u6291\u5236\u5242\u63d0\u4f9b\u4e86\u4f9d\u636e\u3002<\/p>\n<p><b>Focal adhesion kinase (FAK) inhibitor APG-2449 sensitizes ovarian tumors to chemotherapy via CD44 downregulation<\/b><\/p>\n<p><b>\u5c40\u7076\u7c98\u9644\u6fc0\u9176<\/b><b>(FAK)\u6291\u5236\u5242APG-2449\u901a\u8fc7\u4e0b\u8c03CD44\u589e\u5f3a\u5375\u5de2\u764c\u5bf9\u5316\u7597\u7684\u654f\u611f\u6027<\/b><\/p>\n<ul type=\"disc\">\n<li><b>\u6458\u8981\u7f16\u53f7\uff1a<\/b><b>968<\/b> <\/li>\n<li><b>\u80cc\u666f\uff1a<\/b><\/li>\n<\/ul>\n<p>\u5375\u5de2\u764c\u662f\u5973\u6027\u6700\u81f4\u547d\u7684\u6076\u6027\u80bf\u7624\u4e4b\u4e00\uff0c\u9ad8\u8fbe70%\u7684\u5375\u5de2\u4e0a\u76ae\u764c\u60a3\u8005\u5b58\u5728FAK\u8fc7\u8868\u8fbe\u3001\u6269\u589e\u6216\u6fc0\u6d3b\u3002\u540c\u65f6\uff0cFAK\u5728\u7ec6\u80de\u8fc1\u79fb\u3001\u751f\u957f\u56e0\u5b50\u4fe1\u53f7\u8f6c\u5bfc\u3001\u7ec6\u80de\u5468\u671f\u8fd0\u8f6c\u3001\u7ec6\u80de\u7684\u5b58\u6d3b\u548c\u5316\u7597\u836f\u7269\u7684\u8010\u836f\u7b49\u65b9\u9762\u4e5f\u53d1\u6325\u7740\u91cd\u8981\u4f5c\u7528\u3002FAK\u4f5c\u4e3a\u751f\u7269\u6807\u5fd7\u7269\u4e5f\u4e0e\u5375\u5de2\u764c\u60a3\u8005\u80bf\u7624\u5206\u671f\u3001\u80bf\u7624\u8f6c\u79fb\u548c\u7f29\u77ed\u603b\u751f\u5b58\u671f\u663e\u8457\u76f8\u5173\u3002\u56e0\u6b64\uff0c\u5728\u5375\u5de2\u764c\u6cbb\u7597\u4e2dFAK\u4e3a\u4e00\u4e2a\u6709\u524d\u666f\u7684\u4f5c\u7528\u9776\u70b9\u3002APG-2449\u662f\u7531\u4e9a\u76db\u533b\u836f\u81ea\u4e3b\u7814\u53d1\u7684FAK\/ALK\/ROS1\u591a\u9176\u6291\u5236\u5242\uff0c\u76ee\u524d\u5904\u4e8e\u4e34\u5e8a\u4e00\u671f\u3002\u5728\u672c\u7814\u7a76\u4e2d\uff0c\u6211\u4eec\u8bc4\u4ef7\u4e86APG-2449\u4e0e\u6807\u51c6\u5316\u7597\u836f\u7269\u8054\u5408\u6cbb\u7597\u5375\u5de2\u764c\u7684\u6297\u80bf\u7624\u6d3b\u6027\u3002<\/p>\n<ul type=\"disc\">\n<li><b>\u7ed3\u8bba\uff1a<\/b><\/li>\n<\/ul>\n<p>\u4e34\u5e8a\u524d\u7814\u7a76\u6570\u636e\u8868\u660e\uff0c\u5728\u4e34\u5e8a\u524d\u5375\u5de2\u764c\u80bf\u7624\u6a21\u578b\u4e2d\uff0cAPG-2449\u901a\u8fc7\u6291\u5236FAK\u7684\u529f\u80fd\u4ece\u800c\u4f7f\u5375\u5de2\u764c\u5bf9\u5316\u7597\u836f\u7269\u518d\u6b21\u654f\u611f\u3002\u836f\u7269\u7684\u8054\u5408\u901a\u8fc7\u51cf\u5c11\u80bf\u7624\u5e72\u7ec6\u80de\u7684\u6570\u91cf\u5e76\u663e\u793a\u534f\u540c\u6297\u80bf\u7624\u6d3b\u6027\u3002\u4ee5\u4e0a\u7ed3\u679c\u5c06\u6709\u52a9\u4e8e\u63a8\u52a8APG-2449\u8054\u5408\u5316\u7597\u836f\u7269\u5728\u6cbb\u7597\u5375\u5de2\u764c\u4e0a\u7684\u4e34\u5e8a\u8fdb\u5c55\u3002<\/p>\n<p><b><u>\u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/u><\/b><\/p>\n<p>\u4e9a\u76db\u533b\u836f\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u56fd\u3001\u9762\u5411\u5168\u7403\u7684\u5904\u4e8e\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u7684\u539f\u521b\u65b0\u836f\u7814\u53d1\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u7684\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9a\u76db\u533b\u836f\u5728\u9999\u6e2f\u8054\u4ea4\u6240\u4e3b\u677f\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1a6855.HK\u3002<\/p>\n<p>\u4e9a\u76db\u533b\u836f\u62e5\u6709\u81ea\u4e3b\u6784\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u836f\u7269\u8bbe\u8ba1\u5e73\u53f0\uff0c\u5904\u4e8e\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u836f\u7814\u53d1\u7684\u5168\u7403\u6700\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u62e5\u67098\u4e2a\u5df2\u8fdb\u5165\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u76841\u7c7b\u5c0f\u5206\u5b50\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP \u6216 MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u8def\u5f84\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\uff1b\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u7b49\uff0c\u4e3a\u5168\u7403\u552f\u4e00\u5728\u7ec6\u80de\u51cb\u4ea1\u8def\u5f84\u5173\u952e\u86cb\u767d\u9886\u57df\u5747\u6709\u4e34\u5e8a\u5f00\u53d1\u54c1\u79cd\u7684\u521b\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u56fd\u3001\u7f8e\u56fd\u53ca\u6fb3\u5927\u5229\u4e9a\u5f00\u5c5540\u591a\u9879I\/II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\u7528\u4e8e\u6cbb\u7597\u8010\u836f\u6027\u6162\u6027\u9ad3\u6027\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u79cdHQP1351\u5df2\u5728\u4e2d\u56fd\u9012\u4ea4\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\uff0c\u5e76\u83b7\u7eb3\u5165\u4f18\u5148\u5ba1\u8bc4\u3002\u8be5\u54c1\u79cd\u8fd8\u83b7\u5f97\u4e86\u7f8e\u56fdFDA\u5ba1\u8bc4\u5feb\u901f\u901a\u9053\u53ca\u5b64\u513f\u836f\u8ba4\u8bc1\u8d44\u683c\u3002\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u4e2a\u5728\u7814\u65b0\u836f\u83b7\u5f9711\u9879FDA\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u8bc1\u3002<\/p>\n<p><b><u>\u524d\u77bb\u6027\u58f0\u660e<\/u><\/b><\/p>\n<p>\u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u4e0e\u672c\u6587\u4f5c\u51fa\u8be5\u9648\u8ff0\u5f53\u65e5\u7684\u4e8b\u4ef6\u6216\u8d44\u6599\u6709\u5173\u3002\u9664\u6cd5\u5f8b\u89c4\u5b9a\u5916\uff0c\u4e8e\u4f5c\u51fa\u524d\u77bb\u6027\u9648\u8ff0\u5f53\u65e5\u4e4b\u540e\uff0c\u65e0\u8bba\u662f\u5426\u51fa\u73b0\u65b0\u8d44\u6599\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u6211\u4eec\u5e76\u65e0\u8d23\u4efb\u66f4\u65b0\u6216\u516c\u5f00\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u53ca\u9884\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8bf7\u7ec6\u9605\u672c\u6587\uff0c\u5e76\u7406\u89e3\u6211\u4eec\u7684\u5b9e\u9645\u672a\u6765\u4e1a\u7ee9\u6216\u8868\u73b0\u53ef\u80fd\u4e0e\u9884\u671f\u6709\u91cd\u5927\u5dee\u5f02\u3002\u672c\u6587\u5185\u6240\u6709\u9648\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u53d1\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u6765\u53d1\u5c55\u800c\u51fa\u73b0\u53d8\u52a8\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\">  <\/div>\n<p>\u76f8\u5173\u94fe\u63a5 :<\/p>\n<p>http:\/\/www.ascentagepharma.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022021\u5e744\u670813\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u5904\u4e8e\u4e34\u5e8a\u9636\u6bb5\u7684\u7814\u53d1\u4f01\u4e1a &#8212; \u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u57282021\u7f8e\u56fd\u764c\u75c7\u7814\u7a76\u534f\u4f1a\uff08AACR\uff09\u5e74\u4f1a\u4e0a\u5c55\u793a\u4e86\u4e94\u4e2a\u5728\u7814\u539f\u521b\u65b0\u836f\u7684\u591a\u9879\u6700\u65b0\u4e34\u5e8a\u524d\u8fdb\u5c55\uff0c\u6d89\u53ca\u591a\u4e2a\u764c\u79cd\uff0c\u5e76\u5448\u73b0\u591a\u79cd\u8054\u5408\u7528\u836f\u7684\u6f5c\u529b\u3002 AACR\u5e74\u4f1a\u662f\u5168\u7403\u5386\u53f2\u6700\u60a0\u4e45\u3001\u89c4\u6a21\u6700\u5927\u7684\u80bf\u7624\u7814\u7a76\u5b66\u672f\u4f1a\u8bae\u4e4b\u4e00\u3002\u4f1a\u8bae\u5173\u6ce8\u9ad8\u8d28\u91cf\u80bf\u7624\u7814\u7a76\u53ca\u521b\u65b0\u7684\u5404\u4e2a\u65b9\u9762\uff0c\u662f\u5168\u7403\u80bf\u7624\u7814\u7a76\u7684\u7126\u70b9\uff0c\u5c06\u6c47\u96c6\u80bf\u7624\u9886\u57df\u7684\u6700\u524d\u6cbf\u7684\u7814\u7a76\u6210\u679c\u3002 \u4e9a\u76db\u533b\u836f\u5171\u6709\u4e03\u9879\u7814\u7a76\u6210\u679c\u5165\u9009\u672c\u6b21AACR\u5e74\u4f1a\u58c1\u62a5\u5c55\u793a\uff1a \u4ea7\u54c1 \u6807\u9898 \u6458\u8981\u7f16\u53f7 HQP1351 FMS-like tyrosine kinase 3 (FLT3) inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 in preclinical models of FLT3-mutant acute myeloid leukemia (AML) FMS\u6837\u916a\u6c28\u9178\u6fc0\u91763 (FLT3) \u6291\u5236\u5242\u5965\u745e\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u901a\u8fc7\u4e0b\u8c03MCL-1\u4e0eBCL-2\u6291\u5236\u5242APG-2575\u5728FLT3\u7a81\u53d8\u578b\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5(AML)\u7684\u4e34\u5e8a\u524d\u6a21\u578b\u4e2d\u7684\u534f\u540c\u4f5c\u7528 1096 ATP-site inhibitor olverembatinib, HQP1351, enhanced the effect of allosteric inhibitor on the resistance&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/2021041307240026265\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":8278,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-26265","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/26265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=26265"}],"version-history":[{"count":2,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/26265\/revisions"}],"predecessor-version":[{"id":26268,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/26265\/revisions\/26268"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/8278"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=26265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=26265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=26265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}